Dr. Patricia Martin, Chief Operating Officer of LimmaTech, stated, "The start of this trial is a significant milestone for the S4V2 program and our combined efforts with Valneva to bring an effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback